Daniel Sargent on International Collaboration for Colon Cancer Research

Daniel Sargent, PhD
Published: Thursday, Jun 30, 2016



Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

To conduct the study, Sargent said that more than 10,000 patients had to be enrolled. Therefore, 6 different trials were conducted around the world, with a total of more than 12,000 patients. The results of the trial have not yet been released.

Sargent emphasized that international data sharing and collaboration is important, not only for trials that need to be very large, but also for studies dealing with rare subtypes, where any one country may not have enough patients willing to participate.

<<< View more from the 2016 World Congress on GI Cancer



Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

To conduct the study, Sargent said that more than 10,000 patients had to be enrolled. Therefore, 6 different trials were conducted around the world, with a total of more than 12,000 patients. The results of the trial have not yet been released.

Sargent emphasized that international data sharing and collaboration is important, not only for trials that need to be very large, but also for studies dealing with rare subtypes, where any one country may not have enough patients willing to participate.

<<< View more from the 2016 World Congress on GI Cancer


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x